Project Grant R01CA301624
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $656K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, DC 20057, USA
Similar Awards
- Federal Grant Award Summary Georgetown University received a $429,000 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded on April 16, 2026, with an ultimate completion date of March 31, 2028. The award funds research to identify and validate epigenetic biomarkers in glioblastoma (GBM), the most common malignant primary brain tumor in adults....
- Federal Grant Award Summary Georgetown University received a $401,115 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), awarded May 7, 2026, with completion targeted for April 30, 2028. The award supports the development and refinement of targeted nanoparticle therapy strategies for pancreatic ductal adenocarcinoma (PDAC), a disease characterized by poor prognosis, dense fibrosis, immunosuppression, and limited...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $1.88 million Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) on September 23, 2025. The award supports a four-year research initiative (through August 31, 2029) focused on integrating genome-wide association study (GWAS) data with single-cell omics technologies to identify and characterize the cellular effectors responsible for...
- Federal Grant Award Summary Georgetown University received a $754,873 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026, through June 30, 2029. The award supports research targeting WNK1 (With-No-Lysine Kinase 1) to disrupt cell volume control mechanisms in triple-negative breast cancer. This research initiative falls within the Defense Health Agency's broader portfolio of hypothesis-driven biomedical...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Princeton University a Project Grant of $544,480 (awarded April 1, 2026; completion date March 31, 2031) under the Cancer Treatment Research program (CFDA 93.395) to discover and synthesize novel cryptic enediynes and microbial cytotoxins with anticancer potential. The research leverages high-throughput elicitor screening (HITES) methodology to access metabolites encoded by transcriptionally silent biosynthetic...
- Federal Project Grant Award Summary Massachusetts General Hospital (MGH), through its Research Management Division, received a $707,798 project grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective April 1, 2026 through March 31, 2031. The award funds research to determine mechanisms of heterogeneous treatment response in glioblastoma (GBM), an aggressive brain tumor that typically recurs in treatment-refractory form shortly after...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Georgia State University Research Foundation Inc. a $406,258 Project Grant on July 15, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop novel covalent anti-cancer drugs utilizing phosphorus fluoride exchange (PFEX) click chemistry. The two-year research initiative, concluding June 30, 2027, focuses on designing privileged covalent warheads with expanded target scopes to overcome limitations of...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $395,846 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to conduct research on therapeutic targeting of SMARCAL1 in therapy-resistant gliomas. The award, dated April 1, 2026, with completion scheduled for March 31, 2031, supports fundamental laboratory research aimed at identifying and validating novel therapeutic vulnerabilities in Alternative...
- Project Grant Summary Georgetown University received a $663,383 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) on August 1, 2025, to support proactive outreach and streamlined genetic testing initiatives for prostate cancer survivors. The project, extending through July 31, 2030, addresses the critical gap between expanded germline genetic testing guidelines and low testing rates among the nation's over three million...
- Georgetown University received a $395,356 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025, through July 31, 2027. The award supports fundamental research to elucidate the mechanisms of glucocorticoid receptor (GR) signaling in triple negative breast cancer (TNBC) progression, specifically investigating how a small population of "enabler" cells drive invasiveness and metastasis in the bulk tumor...